Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets

These therapeutics generated 4 Investigational New Drug (IND) applications and over 104 clinical studies involving more than 15,000 subjects across a number of CNS indications.

Terran plans to quickly advance the development of these assets for neurological and psychiatric indications, which include several novel applications where there is a large unmet medical need. This transaction represents the key next stage in the development of these promising assets.

The deal included an upfront payment as well as typical success-based milestones and royalties. Specific financial terms of the deal were not disclosed.

"We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry," stated Dr. Sam Clark, Terran's Founder and CEO.

About Terran Biosciences, Inc.
Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing of number of late-stage assets, which include novel psychedelic-based therapeutics.

Terran Contact

Investor Relations:
[email protected]

Media:
[email protected]

Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg 

• ข่าวTerran Biosciences
• ข่าวo:editor
• ข่าวo:c_med
• ข่าวo:prnus
• ข่าวo:heal